Skip to main content Skip to search Skip to main navigation

EDQM: Ph. Eur. Pre-Publishes Cannabis Flower Monograph

The new monograph on Cannabis flower (3028) will be published in Ph. Eur. Supplement 11.5 in January 2024. Given the exceptionally high interest from stakeholders in having access to the new text as soon as possible, the Ph. Eur. decided to make the monograph immediately available on the EDQM website for information.

The new text covers the herbal drug defined as the dried, whole or fragmented, fully developed female inflorescences of Cannabis sativa L. It is to be read in conjunction with the general monograph Herbal drugs (1433), which includes additional requirements that are applicable unless otherwise stated in the Cannabis flower monograph.

The new monograph takes into account information received from a number of national authorities concerning the use of the herbal drug in their jurisdictions: it can be employed as a raw material for the production of extracts or it can be prescribed as is, to be taken by patients by inhalation or oral administration. Additional requirements have been included in the limits for content, in the production section and in the tests for foreign matter, arsenic, cadmium and lead for cases in which the herbal drug is to be prescribed to patients.

The EDQM will hold a webinar on 14 December 2023 (15:30 – 17:00 CET) to present the new monograph to its stakeholders to help them prepare for implementation of the text as of 1 July 2024. You can register here.


Source:

EDQM Newsroom

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What are the quality requirements for pharmaceutical gases?

What are the quality requirements for pharmaceutical gases?

You can view the answer here:
Read more
EMA: Update on the Guideline “Stability Testing for Variations”

EMA: Update on the Guideline “Stability Testing for Variations”

The EMA has updated the guideline on stability testing for variations (Revision 3, applicable from 15 January 2026).
Read more
EU: Proposal for Simplification of Medical Device Rules

EU: Proposal for Simplification of Medical Device Rules

The European Commission has proposed targeted reforms to simplify the Medical Device Regulation (Regulation (EU) 2017/745, MDR) and the In Vitro Diagnostic Regulation (Regulation (EU) 2017/746, IVDR) and to address structural implementation challenges.
Read more
EU: Proposal for a European Biotech Act

EU: Proposal for a European Biotech Act

The European Commission has presented a proposal for a European Biotech Act aimed at strengthening Europe’s biotechnology potential and accelerating the translation of innovation from the laboratory to the market.

Read more
EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

The EMA has published a concept paper outlining a future revision of Annex 3 (Manufacture of Radiopharmaceuticals) of the EU GMP Guidelines. The paper was developed in collaboration with PIC/S and adopted by the GMDP Inspectors Working Group (IWG) at its November meeting.

Read more
EMA: Q&A on QP Certification Without Physical EU Import

EMA: Q&A on QP Certification Without Physical EU Import

The EMA has published a new Q&A addressing QP certification for batches that are neither manufactured within the EU/EEA nor intended for the EU/EEA market, and that are not physically imported into the EU/EEA.

Read more
Previous
Next